What Rice Biotech Launch Pad does

Rice Biotech Launch Pad is a nonprofit university-affiliated biotech accelerator, formally established in 2023 and operated as an initiative of Rice University in Houston, Texas. Its core function is to translate health and medical technology discoveries from Rice University laboratories into clinical applications and commercial ventures. The organization integrates Rice's bioengineering, bioelectronics, materials science, and chemistry faculty with the Texas Medical Center clinical ecosystem, and supports a postdoctoral fellows program as a talent pipeline for venture creation. Rice Biotech Launch Pad does not sell commercial products; its outputs are research outputs, clinical development collaborations, licensing arrangements, and equity stakes in spun-out companies.

The accelerator's technical platform centers on several proprietary research areas developed by Rice faculty: engineered cell therapeutic devices for cancer and wound healing (Veiseh Lab); implantable 'living pharmacy' technology capable of producing therapeutics in vivo (drug factory implants cleared for human trials in August 2022); and bioelectronic therapeutics for neurological conditions including major depressive disorder. These platforms have already produced FDA-cleared clinical-stage assets and form the IP base for portfolio companies. The accelerator's wholly-owned subsidiary, RBL LLC (created October 2024, officially launched May 2025), provides dedicated lab and office space at Helix Park within the Texas Medical Center for venture creation.

Rice Biotech Launch Pad's revenue model is grant- and donation-driven rather than commercial. Funding sources include DARPA (NTRAIN, REPAIR, and a $22M grant for wound healing technology), the Bill and Melinda Gates Foundation (Cell Factories), ARPA-H (THOR project as part of the Cancer Moonshot), and the Cancer Prevention and Research Institute of Texas. Commercial value capture flows through RBL LLC's venture creation activities and licensing arrangements. Portfolio companies spun out of the ecosystem include Avenge Bio ($45M Series A, January 2022), Motif Neurotech ($18.75M Series A, January 2024), and Duracyte (launched April 2026). The program is led by Faculty Director Omid Veiseh (elected to the Controlled Release Society College of Fellows in 2024) and Executive Director Paul Wotton, supported by an 11-person leadership team and a 17-member External Advisory Board drawn from venture capital, pharma, healthcare systems, and academia.

Name

Rice Biotech Launch Pad

Legal name

Rice University Biotech Launch Pad

Website

https://biotechlaunchpad.rice.edu

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Rice Biotech Launch Pad is a nonprofit university-affiliated biotech accelerator that translates Rice University bioengineering, bioelectronic, and cell therapy discoveries into clinical ventures. It funds research with DARPA, Gates, and ARPA-H grants and creates spinout companies via its RBL LLC subsidiary.

Ownership category

akta.pro rank

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Research Grants and Sponsored Funding: Funded by government agencies (DARPA, ARPA-H), private foundations (Bill & Melinda Gates Foundation), and federal programs (Cancer Moonshot) to advance specific research projects.
2. Venture Creation via RBL LLC: RBL LLC creates and spins out biotech startups from Rice University technologies, potentially generating equity returns and commercialization revenue.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Rice Biotech Launch Pad is a university-based biotech accelerator that translates biomedical discoveries from Rice University laboratories into clinical applications. Operating within the Texas Medical Center ecosystem in Houston, it provides infrastructure, funding, mentorship, and venture creation support to develop therapeutics in cell therapy, bioelectronic medicine, and regenerative biology. Its portfolio includes spinout companies and federally funded research programs such as DARPA NTRAIN, DARPA REPAIR, ARPA-H THOR, and Gates Cell Factories.

Product overview

Rice Biotech Launch Pad is a university-based biotech accelerator focused on translating discoveries from Rice University laboratories into clinical applications. The organization operates as a hub for innovative research, supporting multiple project initiatives including bioelectronic therapeutics, cell-based therapies, and implantable 'living pharmacy' technologies. The portfolio includes spun-out companies Avenge Bio (cell therapy for ovarian cancer) and Motif Neurotech (bioelectronic implants), with active research projects in wound healing, cancer treatment, diabetes therapy, and infectious disease. The accelerator integrates with the Houston Texas Medical Center ecosystem and Helix Park for venture creation and laboratory space.

Differentiator

Problem solved

Functional benefit

Brands

• RBL LLC: Venture creation entity launched by Rice Biotech Launch Pad to rapidly create biotech startups focused on delivering breakthrough therapies to patients

Products and services

• Avenge Bio Avenge Bio is a portfolio company developed with the Rice Biotech Launch Pad, focused on engineered cell therapies for cancer and other diseases.
• Motif Neurotech Motif Neurotech is a portfolio company developing minimally invasive bioelectronic therapeutics for neuropsychiatric and neurological disorders.
• Duracyte Duracyte is a portfolio company spun out of the Rice Biotech Launch Pad, working on regenerative biology and tissue engineering applications.
• RBL LLC (Venture Creation Arm) RBL LLC is the dedicated venture creation entity that forms, funds, and supports new therapeutic companies emerging from Rice University research and the Rice Biotech Launch Pad.
• Postdoctoral Fellows Program The Postdoctoral Fellows Program recruits and trains translational scientists who work on Rice Biotech Launch Pad programs and serve as founders for new spinout companies.
• BETx Workshop Series BETx is a workshop and symposium series focused on bioelectronic therapeutics that brings together researchers, clinicians, and industry partners to advance the field.

Quantifiable outcome

• Avenge Bio spun out with $45M Series A; Motif Neurotech raised $18.75M Series A; Duracyte launched in 2026

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and major.

• RBL LLCcoreStrategic or Co-development PartnerRBL LLC is the venture creation arm of Rice Biotech Launch Pad, launched in October 2024. It is a cutting-edge space at Helix Park in Houston's Texas Medical Center designed to accelerate biotech breakthroughs by rapidly creating startups focused on delivering breakthrough therapies to patients.
• Texas Medical CentercoreStrategic or Co-development PartnerRice Biotech Launch Pad is integrated into the Texas Medical Center ecosystem, the world's largest medical complex. William McKeon, President and CEO of Texas Medical Center, serves on the External Advisory Board.
• Rice Global Paris CentermajorStrategic or Co-development PartnerCo-hosts the BioElectronic Therapeutics (BETx) workshop series at the Rice Global Paris Center, bringing together international leaders from biotech/pharma, academia, venture capital, and government.
• Rice UniversitycoreStrategic or Co-development PartnerRice Biotech Launch Pad is an official initiative of Rice University, leveraging the university's faculty, research infrastructure, and academic programs including the Jones Graduate School of Business.
• Helix ParkcoreStrategic or Co-development PartnerRBL LLC operates at Helix Park within the Texas Medical Center campus, providing state-of-the-art lab and office space for biotech startup creation.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cedars-Sinai Accelerator: Hospital-based accelerator (powered by Techstars) that mentors early-stage healthcare companies and provides clinical validation access. Comparable to RBL in providing clinical ecosystem access, though Cedars-Sinai Accelerator focuses on external startup cohorts rather than internal faculty spinouts.
• BioGenerator: St. Louis-based nonprofit biotech venture creation engine that funds, incubates, and builds companies from local research institutions (notably Washington University). Comparable to RBL as an academic-affiliated accelerator that combines lab space, seed capital, and operational support for early-stage biotech startups.
• Mount Sinai Innovation Partners: Icahn School of Medicine at Mount Sinai's tech transfer and venture creation arm responsible for commercialization of faculty discoveries. Comparable in mission to RBL as a major medical-school-based technology licensing and company-creation entity.
• QB3 (California Institute for Quantitative Biosciences): UC-wide biotech innovation accelerator affiliated with UC Berkeley, UCSF, and UC Santa Cruz. Operates startup incubators, venture-stage funding, and faculty spinout support — directly comparable in mission to RBL, focused on translating university bioscience research into companies.
• Stanford SPARK Program: Stanford University's translational medicine program that funds and mentors faculty-led drug discovery and device projects toward commercialization. Closely comparable to RBL in structure — embedded within a research university, faculty-submitted projects, supported by industry mentors, and focused on bridging bench-to-bedside translation.
• Portal Innovations: Chicago- and Houston-based biotech venture firm that combines wet-lab incubator space with seed-stage investment in life sciences startups. Portal Innovations has a presence at Helix Park in the Texas Medical Center alongside RBL, with comparable focus on early-stage biotech venture creation in shared lab infrastructure.
• MIT linQ (Koch Institute): MIT's biomedical technology translation program that funds collaborative projects between MIT engineers and clinicians to develop medical devices and diagnostics. Comparable to RBL in faculty-driven project structure, focus on bioengineering translation, and emphasis on industry partnerships.
• UCSF Rosenman Institute: UCSF-affiliated health technology accelerator that supports founders developing medical devices, diagnostics, and digital health products. Directly comparable to RBL as a major research-university-affiliated translational program targeting biotech and medtech commercialization.

Broad incumbents

• Flagship Pioneering: Cambridge-based biotech venture creation firm (creator of Moderna) that originates and builds platform biotech companies internally. Comparable to RBL as a venture creation engine for biotech, but operates at much larger scale with proprietary institutional capital rather than university grant funding.
• NCATS (National Center for Advancing Translational Sciences): NIH institute focused on accelerating translational science through programs like the CTSA network, Bridging Interventional Development Gaps, and the Rare Diseases Clinical Research Network. A broader federal incumbent in translational research with overlapping mission to RBL, but operating at national scale rather than a single university ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/ricelaunchpad

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rice Biotech Launch Pad